KIT and systemic mastocytosis: Pre-trial and on-treatment NGS using multi-gene panels should also be included as a standard secondary endpoint to analyze additional somatic mutations beyond KIT D816V, especially high-risk mutations (SRSF2, ASXL1, and RUNX1, e.g., S/A/R) which are commonly present in SM-AHN.